Skip to main content

Table 3 Comparison of chemotherapy response in TNBC and non-TNBC patients overexpressing or not BRCA1-IRIS

From: The role of BRCA1-IRIS in the development and progression of triple negative breast cancers in Egypt: possible link to disease early lesion

Clinical response CR SD PD χ2 p-value Total
IRIS+
TNBC
Non-TNBC
12
4
8
2
0
2
29
24
5
9.575 0.0020 43
IRIS
TNBC
Non-TNBC
39
6
33
5
0
3
11
7
4
10.521 0.0052 53
Total 51 5 40    96
  1. χ2 is Chi Square test, Abbreviations: TNBC triple negative breast cancer, CR complete response, SD stable disease, PD progressive disease